Omcazio™.
OMCAZIO™
(cabozantinib)
OMCAZIO™
Indication
OMCAZIO is a kinase inhibitor indicated for the treatment of:
- Patients with advanced renal cell carcinoma (RCC).
- Patients with advanced renal cell carcinoma, as a first-line treatment in combination with nivolumab.
- Patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
- Adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET).
Status
- FDA NDA final approval